{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004194","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.576918+00:00","generated_at":"2026-06-20T18:05:01.053760+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ORIC outlines 2023 milestones: initial Phase 1b data expected H2 2023 for three programs","bullets":["Initial Phase 1b data expected H2 2023 for ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2 cancers), ORIC-944 (prostate cancer).","Pfizer invested $25M in ORIC common stock as part of ORIC-533 clinical collaboration.","Cash and investments $228M as of Dec 31, 2022; runway into H1 2025.","Selected PLK4 inhibitor as development candidate for breast cancer (TRIM37-amplified) in Q4 2022.","All three clinical programs dose-escalating steadily without reaching MTD; global site expansion ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004194","json":"https://secwatch.observer/filing/0001193125-23-004194.json","markdown":"https://secwatch.observer/filing/0001193125-23-004194.md","text":"https://secwatch.observer/filing/0001193125-23-004194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312523004194/0001193125-23-004194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312523004194/d448025d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:05:01.053760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}